natgillin/translations-raw huggingface dataset:
Therapy should be reinitiated at approximately 25% lower than the previous dose after haemoglobin levels fall to 12 g/dL (7.5 mmol/L) or below. 
Liječenje treba ponovo početi s otprilike 25% nižom dozom od prethodne nakon što vrijednost hemoglobina padne na 12 g/dl (7,5 mmol/l) ili niže.
It is important that you do not try to give yourself the injection unless you have received training from your doctor, nurse or pharmacist. 
Važno je da ne pokušavate sami sebi dati injekciju ukoliko niste prošli obuku kod svojeg liječnika, medicinske sestre ili ljekarnika.
Not known: frequency cannot be estimated from available data • Pure red cell aplasia (PRCA) - (anaemia, unusual tiredness, lack of energy) 
• izolirana aplazija crvenih krvnih stanica (PRCA) - (anemija, neuobičajeni umor, nedostatak energije)
If you want to use the same injection site, make sure it is not the same spot on the injection site you used for a previous injection. 
Ukoliko morate upotrijebiti isto mjesto injiciranja, provjerite da to ne bude baš ista točka na tom mjestu u koje ste injicirali prošli put.
If you have forgotten a dose of Aranesp, you should contact your doctor to discuss when you should inject the next dose. 
Ako ste zaboravili primijeniti dozu lijeka Aranesp, odmah se obratite svojem liječniku da Vas uputi kad trebate uzeti sljedeću dozu.
Put the original carton with any unused pre-filled pens back in the refrigerator. 
Vratite originalno pakiranje s neupotrebljenim napunjenim štrcaljkama natrag u hladnjak.
In a prospective, randomised double-blind, placebo-controlled study conducted in 314 lung cancer patients receiving platinum containing chemotherapy there was a significant reduction in transfusion requirements (p < 0.001). 
U prospektivnom, randomiziranom, dvostruko slijepom, placebom kontroliranom ispitivanju provedenom na 314 bolesnika s rakom pluća koji su primali kemoterapiju koja sadrži platinu postojalo je znatno smanjenje potreba za transfuzijom (p < 0,001).
Pooled post-hoc analyses of clinical studies of ESAs have been performed in chronic renal failure patients (on dialysis, not on dialysis, in diabetic and non-diabetic patients). 
Provedena je post-hoc analiza objedinjenih podataka iz kliničkih ispitivanja LSE-a u bolesnika s kroničnim zatajenjem bubrega (koji su na dijalizi, koji nisu na dijalizi, kod dijabetičara i ne-dijabetičara).
Aranesp is used to treat symptomatic anaemia that is associated with chronic renal failure (kidney failure) in adults and children. 
Aranesp se primjenjuje u liječenju simptomatske anemije povezane s kroničnim zatajenjem bubrega u odraslih osoba i djece.
In patients with a poor haemoglobin response to epoetins, alternative explanations for the poor response should be considered (see sections 4.2 and 5.1). 
U bolesnika s nedovoljnim odgovorom hemoglobina na epoetine, treba razmotriti druga objašnjenja za nedovoljan odgovor na liječenje (vidjeti dijelove 4.2 i 5.1).
Significantly fewer patients received RBC transfusions in the epoetin alfa plus SOC arm (5.8% versus 11.4%); however, significantly more patients had thrombotic vascular events in the epoetin alfa plus SOC arm (2.8% versus 1.4%). 
Znatno manji broj bolesnika primio je transfuziju crvenih krvnih stanica u skupini koja je primala epoetin alfa i standardnu zdravstvenu skrb (5,8% naspram 11,4%); međutim, značajno više bolesnika imalo je trombotske vaskularne događaje u skupini koja je primala epoetin alfa i standardnu zdravstvenu skrb (2,8% naspram 1,4%).
The pharmacokinetics of darbepoetin alfa in paediatric patients (2 to 16 years) with CRF who were either receiving or not receiving dialysis was assessed for sampling periods up to 2 weeks (336 hours) after one or two subcutaneous or intravenous doses. 
Farmakokinetika darbepoetina alfa kod pedijatrijskih bolesnika (2 do 16 godina) s kroničnim zatajenjem bubrega koji su bili na dijalizi i onih koji nisu, je ocijenjena za periode uzorkovanja do 2 tjedna (336 sati) nakon jedne ili dvije supkutane ili intravenske doze.
Aranesp is used to treat symptomatic anaemia in adult cancer patients with non-bone marrow cancers (non-myeloid malignancies) who are receiving chemotherapy. 
Aranesp se primjenjuje u liječenju simptomatske anemije u odraslih osoba koje boluju od raka koji podrijetlom nije iz koštane srži (nemijeloične maligne bolesti) i primaju kemoterapiju.
Meta-analysis of overall survival data produced a hazard ratio point estimate of 1.08 in favour of controls (95% CI: 0.99, 1.18; 42 trials and 8,167 patients). 
Metaanaliza podataka sveukupnog preživljenja dala je procjenu omjera rizika sveukupnog preživljenja od 1,08 u korist kontrolne skupine (95% CI: 0,99; 1,18; 42 ispitivanja i 8167 bolesnika).
Clinical data in paediatric patients has demonstrated that patients receiving r-HuEPO two or three times weekly may be converted to once weekly Aranesp, and those receiving r-HuEPO once weekly may be converted to once every other week Aranesp. 
Klinička ispitivanja su pokazala da pedijatrijski bolesnici koji primaju r-HuEPO 2 ili 3 puta tjedno mogu prijeći na primjenu lijeka Aranesp jednom tjedno, a oni koji primaju r-HuEPO jednom tjedno mogu prijeći na primjenu lijeka Aranesp jednom svaka 2 tjedna.
PHARMACEUTICAL FORM AND CONTENTS 1 single use vial 
OBLIK I SADRŽAJ 1 bočica za jednokratnu uporabu
The longer terminal half-life of darbepoetin alfa administered subcutaneously compared to intravenously is due to subcutaneous absorption kinetics. 
Poluvijek darbepoetina alfa primijenjenog supkutano, u usporedbi s intravenskom primjenom, je dulji zbog kinetike supkutane apsorpcije.
Rash/erythemac 
Osip/eritemc
Meta-analysis of overall survival data produced a hazard ratio point estimate of 1.06 in favour of controls (95% CI: 1.00, 1.12; 53 trials and 13,933 patients) and for the cancer patients receiving chemotherapy, the overall survival hazard ratio was 1.04 (95% CI: 0.97, 1.11; 38 trials and 10,441 patients). 
Metaanaliza sveukupnog preživljenja pokazala je procijenjeni omjer rizika od 1,06 u korist kontrola (95% CI: 1,00; 1,12; 53 ispitivanja i 13 933 bolesnika) i za bolesnike s rakom koji su primali kemoterapiju, ukupni omjer rizika preživljenja je bio 1,04 (95% CI: 0,97; 1,11; 38 ispitivanja i 10 441 bolesnika).
Patients were randomised to receive Aranesp at 500 mcg once every three weeks or 2.25 mcg/kg once weekly. 
Bolesnici su randomizirani za dobivanje 500 μg lijeka Aranesp jednom u 3 tjedna ili 2,25 μg/kg jednom tjedno.
In all cases, call your doctor or healthcare provider. 
U svim navedenim slučajevima, obratite se svom liječniku ili zdravstvenom radniku.
Treatment with Aranesp should be temporarily discontinued if haemoglobin levels exceed 13 g/dL (8.1 mmol/L). 
Liječenje lijekom Aranesp mora se privremeno prekinuti ako vrijednosti hemoglobina prijeđu 13 g/dl (8,1 mmol/l).
In patients with a poor haemoglobin response to Aranesp, alternative explanations for the poor response should be considered (see sections 4.4 and 5.1). 
U bolesnika s nedovoljnim odgovorom hemoglobina na Aranesp, treba razmotriti druga objašnjenja za nedovoljan odgovor na liječenje (vidjeti dijelove 4.4 i 5.1).
Hypersensitivitya 
Preosjetljivosta
Inject the prescribed dose subcutaneously as directed by your doctor, nurse or pharmacist. 
Injicirajte propisanu dozu potkožno kako Vas je uputio liječnik, medicinska sestra ili ljekarnik.
Your doctor, nurse or pharmacist will show you how to inject yourself with the pre-filled syringe. 
Liječnik, medicinska sestra ili ljekarnik će Vam pokazati kako ćete sami injicirati lijek.
Hypersensitivity reactions have been observed in cancer patients in post-marketing experience. 
Reakcije preosjetljivosti su primijećene kod bolesnika s rakom, nakon stavljanja lijeka u promet.
Once removed from the refrigerator and has reached room temperature (up to 25ºC) it must either be used within 7 days or disposed of. 
Jednom kad se izvadi iz hladnjaka i dostigne sobnu temperaturu (do 25°C), mora se upotrijebiti u roku 7 dana ili zbrinuti.
• Blood clots in a dialysis access 
• krvni ugrušci u pristupu za dijalizu
Aranesp is a sterile but unpreserved product. 
Aranesp je sterilan lijek, ali bez konzervansa.
• Fluid retention (oedema) 
• zadržavanje tekućine (edem)
• It is important that you do not try to give yourself the injection unless you have received training from your doctor or healthcare provider. 
• Važno je da ne pokušavate dati sebi injekciju ukoliko niste prošli obuku kod svojeg liječnika ili zdravstvenog radnika
PHARMACEUTICAL FORM AND CONTENTS 1 single use pre-filled syringe. 
OBLIK I SADRŽAJ 1 napunjena štrcaljka za jednokratnu uporabu.
The mean haemoglobin at week 28 for r-HuEPO and darbepoetin alfa was 11.1 (SD 1.4) g/dL and 11.1 (SD 1.1) g/dL, respectively. 
Srednja vrijednost hemoglobina u 28. tjednu za r-HuEPO bila je 11,1 (SD 1,4) g/dl, a za darbepoetin alfa 11,1 (SD 1,1) g/dl.
Instructions for injecting with the Aranesp pre-filled syringe This section contains information on how to give yourself an injection of Aranesp. 
Upute za injiciranje lijeka Aranesp u napunjenoj štrcaljki Ovo poglavlje sadrži upute o samoprimjeni injekcije lijeka Aranesp.
Patients should be monitored closely, if the haemoglobin exceeds 12 g/dL (7.5 mmol/L), the dose should be reduced by approximately 25 to 50%. 
Bolesnike treba pažljivo pratiti te ako hemoglobin prijeđe 12 g/dl (7,5 mmol/l), doza se mora smanjiti za otprilike 25 do 50%.
Put the used pre-filled pen in the sharps disposal container immediately after use. 
Odložite iskorištenu brizgalicu u spremnik za odlaganje oštrih predmeta odmah nakon primjene.
• Additional risk minimisation measures for Aranesp solution for injection in pre-filled pen 
• Dodatne mjere minimizacije rizika za Aranesp otopinu za injekciju u napunjenoj brizgalici
Erythropoietin is a growth factor that primarily stimulates red blood cell production. 
Eritropoetin je čimbenik rasta koji primarno stimulira stvaranje crvenih krvnih stanica.
The pharmacokinetics of darbepoetin alfa has been studied clinically in chronic renal failure patients following intravenous and subcutaneous administration. 
Farmakokinetika darbepoetina alfa klinički je ispitivana u bolesnika s kroničnim zatajenjem bubrega tijekom intravenske i supkutane primjene.
For adult patients not on dialysis, 1.5 micrograms/kg once monthly may also be used as the initial dose. 
Za odrasle bolesnike koji nisu na dijalizi, kao početna doza može se primijeniti i 1,5 mikrograma/kg jednom mjesečno.
Leave the pre-filled syringe at room temperature for approximately 30 minutes. 
Ostavite napunjenu štrcaljku oko 30 minuta na sobnoj temperaturi.
During the evaluation period (weeks 29-33), the mean (95% CI) weekly equivalent dose was 0.20 (0.17, 0.24) mcg/kg in the once every two week arm and 0.27 (0.23, 0.32) mcg/kg in the once monthly arm. 
Tijekom razdoblja procjene (29.-33. tjedna), srednja vrijednost (95% CI) tjedne ekvivalentne doze iznosila je 0,20 (0,17, 0,24) μg/kg u skupini koja je primala dozu jednom svaka dva tjedna i 0,27 (0,23, 0,32) μg/kg u skupini koja je primala dozu jednom mjesečno.
It is unknown whether Aranesp is excreted in human milk. 
Nije poznato izlučuje li se Aranesp u majčino mlijeko.
In isolated cases, neutralising anti-erythropoietin antibody mediated pure red cell aplasia (PRCA) associated with Aranesp therapy have been reported predominantly in patients with CRF treated subcutaneously. 
U pojedinim slučajevima, izolirana aplazija crvenih krvnih stanica (PRCA) uzrokovana neutralizirajućim antieritropoetin antitijelima povezana s liječenjem lijekom Aranesp bila je prijavljivana uglavnom kod bolesnika s kroničnim zatajenjem bubrega liječenih supkutano.
With the grey cap off, place the pre-filled pen on your skin at 90 degrees. 
Napunjenu brizgalicu, kojoj ste prethodno skinuli sivi pokrov, postavite na kožu pod pravim kutom (90⁰).
METHOD AND ROUTE(S) OF ADMINISTRATION Read the package leaflet before use. 
NAČIN I PUT(EVI) PRIMJENE LIJEKA Prije uporabe pročitati uputu o lijeku.
• Convulsions (fits and seizures) 
• konvulzije (napadaji)
Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin target range of 10 g/dL (6.2 mmol/L) to 12 g/dL (7.5 mmol/L). 
Varijabilnost hemoglobina treba riješiti prilagođavanjem doze, uzevši u obzir ciljni raspon hemoglobina od 10 g/dl (6,2 mmol/l) do 12 g/dl (7,5 mmol/l).
• an observed 9% increase in risk for PD or death in the epoetin alfa plus SOC group from a primary analysis and a 15% increased risk that cannot be statistically ruled out in patients with metastatic breast cancer receiving chemotherapy when administered to achieve a haemoglobin concentration range of 10 to 12 g/dL (6.2 to 7.5 mmol/L). 
• opaženo povećanje rizika od 9% od progresivne bolesti ili smrti u skupini koja je primala epoetin alfa i standardnu zdravstvenu skrb iz primarne analize i povećanje rizika od 15% koje se ne može statistički isključiti u bolesnika s metastatskim karcinomom dojke koji primaju kemoterapiju kada se primjenjuje radi postizanja ciljne koncentracije hemoglobina od 10 do 12 g/dl (6,2 do 7,5 mmol/l).
Window Medicine Make sure the medicine in the window is a clear and colourless liquid. 
Provjerite da li je lijek vidljiv u prozoru bistra i bezbojna tekućina.
• New pre-filled pen 
• Novu napunjenu brizgalicu
In a clinical study in 124 paediatric patients with chronic kidney disease receiving or not receiving dialysis aged 1 to 18, patients that were stable on epoetin alfa were randomised to receive either darbepoetin alfa administered once weekly (subcutaneously or intravenously) using a dose conversion ratio of 238:1 or to continue with epoetin alfa therapy at the current dose, schedule, and route of administration. 
U kliničkom ispitivanju na 124 pedijatrijska bolesnika u dobi od 1 do 18 godina s kroničnom bolesti bubrega koji jesu ili nisu na dijalizi, bolesnici koji su bili stabilni na liječenju epoetinom alfa, randomizirani su kako bi primali ili darbepoetin alfa jednom tjedno (supkutano ili intravenski) prema omjeru konverzije doza 238:1, ili su nastavili s liječenjem epoetinom alfa u istoj dozi, rasporedu i putu primjene.
J Keep pushing down on your skin. 
Održavajte pritisak na kožu.
Do not put the grey needle cap back on used pre-filled syringes. 
Ne vraćajte sivi pokrov za iglu na iskorištenu štrcaljku.
• Cotton ball or gauze pad 
• Pamučnu vatu ili jastučić gaze
Half-life was also similar between adult and paediatric patients with CRF following both intravenous and subcutaneous administration. 
Poluvijek je također bio sličan kod odraslih i pedijatrijskih bolesnika s kroničnim zatajenjem bubrega nakon obje, intravenske i supkutane primjene.
Do not attempt to activate the pre-filled syringe prior to injection. 
Ne pokušavajte aktivirati napunjenu štrcaljku prije same injekcije.
If after a dose reduction, haemoglobin continues to increase, the dose should be temporarily withheld until the haemoglobin begins to decrease, at which point therapy should be reinitiated at approximately 25% lower than the previous dose. 
Ako nakon smanjenja doze hemoglobin nastavi rasti, mora se privremeno prekinuti liječenje dok se hemoglobin ne počne snižavati, te tada ponovo početi terapiju s dozom otprilike 25% nižom od prethodne.
If you feel unwell in any way you should contact your doctor, nurse or pharmacist immediately. 
Ne osjećate li se dobro na bilo koji način, obratite se odmah svojem liječniku, medicinskoj sestri ili ljekarniku.
The active substance of Aranesp is darbepoetin alfa produced by gene-technology in Chinese Hamster Ovary Cells (CHO-K1). 
Djelatna tvar u lijeku Aranesp je darbepoetin alfa, proizveden genskom tehnologijom na jajnim stanicama kineskog hrčka (CHO-K1).
980211) except for the adverse reaction of stroke which was identified as an adverse reaction in the TREAT 
980117, 980202 i 980211), osim nuspojave moždanog udara koji je uočen kao nuspojava u ispitivanju TREAT
The pre-filled pen is designed to inject the area under your skin only. 
Napunjena brizgalica je dizajnirana za injiciranje samo ispod kože.
If the haemoglobin exceeds 12 g/dL (7.5 mmol/L), a dose reduction should be considered. 
Ako hemoglobin prijeđe 12 g/dl (7,5 mmol/l), treba uzeti u obzir smanjenje doze.
In a randomised, double-blind correction study (n = 358) comparing once every two week and once monthly dosing schedules in patients with CRF not on dialysis, darbepoetin alfa once monthly dosing was non-inferior to once every two week dosing for correcting anaemia. 
U randomiziranom dvostruko slijepom ispitivanju korekcije (n = 358) u kojem su se uspoređivali rasporedi doziranja jednom svaka dva tjedna i jednom mjesečno u bolesnika s kroničnim zatajenjem bubrega koji nisu na dijalizi, doziranje darbepoetina alfa jednom mjesečno nije bilo inferiorno doziranju jednom svaka dva tjedna za korekciju anemije.
There have been reports of serious hypersensitivity reactions including anaphylactic reaction, angioedema, allergic bronchospasm, skin rash and urticaria associated with darbepoetin alfa. 
Prijavljeni su izvještaji ozbiljnih reakcija preosjetljivosti uključujući anafilaktičku reakciju, angioedem, alergijski bronhospazam, kožni osip i urtikariju povezani s darbepoetinom alfa.
For all adults and paediatric patients ≥ 11 years of age not on dialysis, Aranesp could also be given as an injection once monthly. 
Svim odraslim i pedijatrijskim bolesnicima u dobi od ≥ 11 godina, koji nisu na dijalizi, Aranesp se također može davati kao injekcija jednom mjesečno.
• shortened overall survival and increased deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy when administered to target a haemoglobin of 12-14 g/dL (7.5-8.7 mmol/L). 
• skraćenje ukupnog preživljenja i povećanje smrtnosti povezane s napredovanjem bolesti do 4 mjeseca u bolesnika s metastatskim karcinomom dojke koji primaju kemoterapiju kod primjene radi ciljne koncentracije hemoglobina od 12-14 g/dl (7,5-8,7 mmol/l).
Leave the pre-filled pen at room temperature for at least 30 minutes before injecting. 
Ostavite brizgalicu na sobnoj temperaturi najmanje 30 minuta prije injiciranja.
• non-inferiority of darbepoetin alfa to placebo for overall survival and progression free survival in patients with advanced stage non-small cell lung cancer receiving chemotherapy when administered to a target haemoglobin of 12 g/dL (7.5 mmol/L) (see section 5.1). 
• neinferiornost darbepoetina alfa u odnosu na placebo za ukupno preživljenje i preživljenje bez progresije bolesti u bolesnika s uznapredovalim karcinomom pluća nemalih stanica koji primaju kemoterapiju, kada se primjenjuje radi postizanja ciljne koncentracije hemoglobina od 12 g/dl (7,5 mmol/l) (vidjeti dio 5.1).
Caution should be exercised with escalation of Aranesp doses in patients with chronic renal failure. 
Potreban je oprez s povećanjem doze lijeka Aranesp u bolesnika s kroničnim zatajenjem bubrega.
Active liver disease was an exclusion criteria in all studies of Aranesp, therefore no data are available from patients with impaired liver function. 
Ni u jedno ispitivanje lijeka Aranesp nisu bili uključeni bolesnici s aktivnom bolesti jetre pa stoga nema dostupnih podataka o bolesnicima s oštećenom funkcijom jetre.
• Avoid injecting into areas with scars or stretch marks. 
• Izbjegavajte područja s ožiljcima ili strijama.
Pure red cell aplasia 
Izolirana aplazija crvenih krvnih stanica
Step 3: Inject A Hold the pinch. 
Korak 3: Injiciranje A Držite nabor kože među prstima.
Aranesp is available in packs of 1 or 4 pre-filled syringes with automatic needle guard in a blister wrapping. 
Aranesp je dostupan u pakovanjima od 1 ili 4 napunjene štrcaljke s automatskim štitnikom za iglu u blisteru.
The initial dose by subcutaneous or intravenous administration is 0.45 mcg/kg body weight, as a single injection once weekly. 
Početna doza primijenjena supkutano ili intravenski je 0,45 μg/kg tjelesne težine, dana kao pojedinačna injekcija jednom tjedno.
At the time haemoglobin ≥ 10.0 g/dL was first achieved, the mean (SD) weightadjusted dose was 0.48 (0.24) mcg/kg (range: 0.0 to 1.7 mcg/kg) weekly for the once weekly group and 0.76 (0.21) mcg/kg (range: 0.3 to 1.5 mcg/kg) biweekly for the once every two week group. 
Kada je prvi put postignuta vrijednost hemoglobina ≥ 10,0 g/dl, srednja (SD) doza prilagođena za tjelesnu težinu iznosila je 0,48 (0,24) μg/kg (raspon: 0,0 do 1,7 μg/kg) jednom tjedno, za one bolesnike koji su lijek primjenjivali jednom tjedno te 0,76 (0,21) μg/kg (raspon:
d Dialysis vascular access thrombosis includes all adverse reactions under the dialysis vascular access thrombosis 
d Tromboza u vaskularnom pristupu za dijalizu uključuje sve nuspojave navedene u Amgen MedDRA upitu
• A demonstration device 
• Pokazni uređaj
Aranesp should also be used with caution in those patients with sickle cell anaemia. 
Aranesp također uz oprez treba davati i bolesnicima koji boluju od anemije srpastih stanica.
Aranesp should be administered either subcutaneously or intravenously in order to increase haemoglobin to not greater than 12 g/dL (7.5 mmol/L). 
Aranesp treba primijeniti supkutano ili intravenski kako bi se hemoglobin povisio na vrijednost koja nije veća od 12 g/dl (7,5 mmol/l).
Cases of severe hypertension have been observed following overdose with Aranesp (see section 4.4). 
Slučajevi teške hipertenzije zapaženi su nakon predoziranja lijekom Aranesp (vidjeti dio 4.4).
The frequency of all hypersensitivity reactions was estimated from clinical trial data as very common in cancer patients. 
Učestalost svih reakcija preosjetljivosti je procijenjena iz podataka kliničkog ispitivanja kao vrlo česta kod bolesnika s rakom.
In a prospective, randomised double-blind, placebo-controlled study conducted in 344 anaemic patients with lymphoproliferative malignancies receiving chemotherapy there was a significant reduction in transfusion requirements and an improvement in haemoglobin response (p < 0.001). 
U prospektivnom, randomiziranom, dvostruko slijepom, placebom kontroliranom ispitivanju provedenom na 344 anemična bolesnika s limfoproliferativnim malignomima koji su primali kemoterapiju, zabilježeno je znatno smanjenje potreba za transfuzijom i poboljšanje hemoglobinskog odgovora (p < 0,001).
The needle cap of the pre-filled syringe or pre-filled pen contains dry natural rubber (a derivative of latex), which may cause allergic reactions. 
Pokrov igle napunjene štrcaljke ili napunjene brizgalice sadrži suhu prirodnu gumu (derivat lateksa) koja može izazvati alergijske reakcije.
Your doctor has prescribed an Aranesp pre-filled syringe for injection into the tissue just under the skin. 
Liječnik je propisao Aranesp napunjenu štrcaljku za injiciranje u tkivo odmah ispod kože.
Please tell your doctor if you are suffering or have suffered from: - high blood pressure which is being controlled with medicines prescribed by your doctor; - sickle cell anaemia; - epileptic fits (seizures); - convulsions (fits or seizures); - liver disease; - significant lack of response to medicines used to treat anaemia; or - hepatitis C. 
Molimo obavijestite svojeg liječnika, ako bolujete ili ste bolovali od: - visokog krvnog tlaka koji je kontroliran lijekovima koje Vam je propisao liječnik, - anemije srpastih stanica, - epileptičkih napadaja, - konvulzija (napadaji), - bolesti jetre, - značajnog manjka odgovora na lijekove za liječenje anemije, - hepatitisa C.
Incidence of adverse reactions are listed below by system organ class and frequency. 
Incidencija nuspojava je navedena u nastavku prema klasifikaciji organskih sustava i učestalosti.
The terminal half-life of darbepoetin alfa is 21 hours (SD 7.5) when administered intravenously. 
Kod intravenske primjene terminalni poluvijek darbepoetina alfa je 21 sat (SD 7,5).
A Discard the used pre-filled syringe and other supplies in a sharps disposal container. 
Odložite iskorištenu štrcaljku i ostali pribor u spremnik za odlaganje oštrih predmeta.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS TRAY FOR PRE-FILLED SYRINGE WITH NEEDLE GUARD 
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP PODLOŽAK ZA NAPUNJENU ŠTRCALJKU SA ŠTITNIKOM ZA IGLU